Year: 2023

Kinepolis reports strong third quarter following strong first half Regulated information 26 October 2023, 7 a.m. Business update Q3 2023 attached.AttachmentEN Business Update Q3 2023

Pixium Vision announces its financial results for H1 2023 and provides updatePost period event: Received shareholder loan of €3 million from BPIFrance and Sofinnova. Extension of the maturity of outstanding notes €1.25 million, Implemented a reverse stock split, exchanging 50 old to 1 current share, applied for and obtained safeguard proceeding, applied for conversion of the safeguard proceeding to a court-ordered receivership and announced the opening of a process to find a buyer Current cash runway until was extended to the end of December 2023 with the opening of the safeguard proceeding Cash position at 30 June 2023 was €3.7 millionParis, France, October 26, 2023 – 7:00 (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients...

Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose DecisionBoth VIVIAD and VIVA-MIND progressing at 600mg twice daily with oral administration following two independent positive DSMB decisions Varoglutamstat demonstrates very encouraging safety data with no evidence of drug-related ARIAs at therapeutic dose of 600mg twice daily, a dose demonstrated to result in nearly 90% target occupancy On track to report final VIVIAD Phase 2b readout in Q1/2024 Commenced preparations for open label extension study to provide long-term treatment option to patients after completion of treatment under VIVIAD or VIVA-MIND Company to participate at upcoming Jefferies London Healthcare Conference taking place November 14-16, 2023Halle (Saale)...

                                             Mithra and Searchlight Pharma sign DONESTA® licensing agreement for CanadaMithra to receive EUR 1.5 million milestone payout as a result of the signing of the agreement Additional licensing payout of EUR 15.55 million in regulatory and sales milestones, along with tiered royalties on annual net sales Searchlight anticipates filing of Canadian regulatory submission for DONESTA® as a treatment for the symptoms of menopause in H1 2024 Both companies aim to provide innovative solutions to women by partnering on MYRING®, ESTELLE®, and now DONESTA®.Liege, Belgium, and Montreal, Canada, 26 October 2023 – 07:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, and Searchlight Pharma Inc. (“Searchlight”), a private Canadian-specialty pharmaceutical company, have signed...

OSLO, Norway (26 October 2023) – TGS today reported interim financial results for Q3 2023. The quarter reflected a continued improvement in market conditions, with strong growth in both POC revenues (1) and contract inflow. 2023 multi-client investment guidance increased to approximately USD 400 million with a minimum early sales rate of 75%. Financial highlights:POC revenues (1) were USD 293 million compared to USD 119 million in Q3 2022 (+34% pro-forma including Magseis Fairfield ASA). POC EBITDA of USD 170 million versus USD 80 million in Q3 2022 POC operating result was USD 68 million compared to USD -7 million in Q3 2022. Multi-client contract inflow of USD 178 million during Q3 2023 compared to USD 140 million in Q3 2022 – total POC order backlog including Acquisition of USD 475 million Favorable margin development driven...

INTERIM REPORT for 1 January – 30 September 2023 Focus on cost-efficiency in a declining market Verkkokauppa.com Oyj         INTERIM REPORT        26 October 2023, 8:00 a.m. EEST Verkkokauppa.com arranges two virtual news conferences on a result publication day. News conference in Finnish will be held at 10:00 am Finnish time. News conference for analysts and institutional investors in English will be at 11:00 am Finnish time. Details of the events and how to participate can be found at the end of this release. This is a summary of Verkkokauppa.com’s January-September 2023 Interim Report. The complete report is attached to this release and also available at https://investors.verkkokauppa.com/en Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures...

Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through the application of science, today publishes its results for the first nine months of 2023. Key highlights first nine months 2023:Sales € 1,091.0 million; an organic increase of 2.6% Adjusted EBITDA € 142.8 million; an organic increase of 7.1% Operating profit € 75.9 million; an organic growth of 0.2% Organic growth core activities: Sales 4.2% & Adjusted EBITDA 12.3% Q3 2023:Sales € 353.0 million and Adjusted EBITDA € 46.0 million Organic growth core activities: Sales -2.2% & Adjusted EBITDA 6.1%     Positive Free Cash Flow for the 2nd consecutive quarter as anticipatedStrategic Developments:Restructuring program underway to accelerate significant positive free cash flow delivery, including a full review to drive material...

Paris (France), 26 October 2023 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.    YTD 2023 YTD 2022 % change Q3 2023 Q3 2022 % change€m €m Actual CER1 €m €m Actual CER1Oncology 1,744.1 1,767.2 -1.3% 0.8% 574.5 603.1 -4.7% ...

Strong MultiClient Pre-funding Performance Establishing the Premier Energy Data Company Highlights Q3 2023Produced Revenues of $184.8 million, compared to $216.5 million in Q3 2022 Produced EBITDA of $125.7 million, compared to $116.1 million in Q3 2022 Produced EBIT (ex. Impairments and other charges, net) of $20.5 million, compared to $32.6 million in Q3 2022 Revenues and Other Income according to IFRS of $157.3 million, compared to $198.5 million in Q3 2022 Cash flow from operations of $117.6 million, compared to $177.9 million in Q3 2022 Announced intention to merge with TGS to create the premier energy data company Successful completion of $40.6 million private placement $75 million new loan to prepay parts of the 2024 term loan B and extend debt maturity profile Completed acquisition of the first offshore wind site characterization...

PRESS RELEASENantes, 26 October 2023 THIRD-QUARTER AND NINE-MONTH 2023 ACTIVITY Q3 sales at -9.4% consistent with pre-announcementand FY23 guidance adjustment on October 9 3C Plan further strengthened to address changing consumer dynamicsGroup GMV: Q3 at €285.2m (-6.3% yoy), 9M at €896.0m (-5.5% yoy)Marketplace GMV: Q3 at €42.6m (+30.1% yoy), 9M at €127.6m (+56.1% yoy) France GMV: Q3 at €161.9m (-3.3% yoy), 9M at €504.3m (-2.2% yoy)Group sales: Q3 at €252.3m (-9.4% yoy), 9M at €795.7m (-9.8% yoy) 3C Plan: Reinforcing and accelerating all actionsCustomers: Strengthening the Q4 commercial action plan to adapt to consumer behavior, introducing new and distinctive initiatives. Costs: Further increasing selectivity of spending and ensuring a significant outperformance of 2023 cost savings plan, increased from €25 million to €35 million....